Alkermes bounces back after disappointments as depression drug meets study goal
October 21, 2016 at 16:10 PM EDT
Shares of Alkermes are on the rise after the company said its ALKS 5461 for the treatment of a major depressive disorder in patients not helped by standard antidepressants met the main goal in a third late-stage trial.